Polish biotechnology company Mabion (WSE: MAB) believes it is a leading contender to win the race for the global rituximab market.
Rituximab is used to treat rheumatoid arthritis, lupus, vasculitis and dermatomyositis and expiry of Swiss pharma giant Roche’s (ROG: SIX) MabThera patent at the end of 2013 paved the way for the introduction of cheaper versions by biosimilar manufacturers.
Several players were initially involved in chasing the market which at the time was worth more than $7 billion annually.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze